Torigen Pharma's Pipeline

With multiple technologies currently in development, Torigen Pharma will continue to progress tissue vaccine technology, commercializing innovative new approaches to empower veterinarians around the world to tackle companion animal cancer.


Autologous Cancer Vaccine (Vvax-01)

Our Experimental Autologous Cancer Vaccine uses the animal's own tumor cells to create a personalized immunotherapy. 

Vvax-01 is regulated under USDA 9 CFR 103.3. For use under supervision/prescription of a licensed veterinarian. Efficacy and safety have not been established.